AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T18:36:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Tue 29 Apr 25, 09:00 PMCytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
Thu 24 Apr 25, 08:05 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -29.84100M | -5.70000M | -15.70900M | 1.26M | 5.95M |
| Minority interest | 0.00000M | 0.00000M | -0.18900M | -0.09200M | -0.02600M |
| Net income | -66.53900M | -6.02000M | -12.14800M | 2.58M | 4.42M |
| Selling general administrative | 58.94M | 43.11M | 43.97M | 34.69M | 20.82M |
| Selling and marketing expenses | 49.44M | 49.11M | 49.15M | 33.23M | 24.71M |
| Gross profit | 104.46M | 111.11M | 109.43M | 100.97M | 79.14M |
| Reconciled depreciation | 11.97M | 10.49M | 8.67M | 5.66M | 1.24M |
| Ebit | -29.36700M | -20.52300M | -13.63800M | -1.82600M | 6.45M |
| Ebitda | -17.39200M | -10.03300M | -4.40800M | 3.83M | 7.69M |
| Depreciation and amortization | 11.97M | 10.49M | 9.23M | 5.66M | 1.24M |
| Non operating income net other | - | - | - | 5.64M | 0.05M |
| Operating income | -40.38400M | -20.52300M | -27.84500M | -1.82600M | 6.45M |
| Other operating expenses | 241.88M | 220.98M | 220.86M | 165.84M | 118.78M |
| Interest expense | 0.47M | 5.24M | 2.07M | 2.57M | 1.74M |
| Tax provision | 36.70M | 0.32M | -1.77300M | -1.22400M | 1.50M |
| Interest income | 2.22M | 10.36M | 7.59M | 4.62M | 0.05M |
| Net interest income | 1.74M | 10.36M | 5.23M | 2.05M | -1.69200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 36.70M | 0.32M | -3.56100M | -1.22400M | 1.50M |
| Total revenue | 201.49M | 200.45M | 193.01M | 164.04M | 127.95M |
| Total operating expenses | 144.84M | 131.63M | 137.27M | 102.78M | 69.98M |
| Cost of revenue | 97.03M | 89.35M | 83.59M | 63.06M | 48.81M |
| Total other income expense net | 10.54M | 14.82M | 12.14M | 3.09M | -0.49900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -66.53900M | -6.02000M | -13.93300M | 2.48M | 4.44M |
| Net income applicable to common shares | - | - | - | 2.58M | 0.05M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 461.54M | 499.50M | 497.67M | 519.48M | 463.70M |
| Intangible assets | 16.82M | 20.13M | 23.08M | 4.33M | 4.74M |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.91M | 14.10M | 12.32M | 12.95M | 5.50M |
| Total liab | 119.80M | 103.76M | 104.61M | 93.93M | 56.90M |
| Total stockholder equity | 341.74M | 395.74M | 393.06M | 425.30M | 406.46M |
| Deferred long term liab | - | - | - | 13.12M | 9.79M |
| Other current liab | 31.22M | 33.08M | 24.93M | 27.74M | 6.79M |
| Common stock | 0.13M | 0.13M | 0.13M | 0.14M | 0.13M |
| Capital stock | 0.13M | 0.13M | 0.13M | 0.14M | 0.13M |
| Retained earnings | -101.73800M | -35.19900M | -29.17800M | -17.03000M | -18.19000M |
| Other liab | - | - | - | 30.31M | 24.74M |
| Good will | 16.70M | 16.66M | 16.18M | 10.14M | 10.14M |
| Other assets | - | - | 0.00000M | 21.82M | 10.91M |
| Cash | 90.85M | 98.72M | 167.63M | 296.60M | 364.62M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 77.80M | 67.66M | 56.23M | 49.04M | 32.16M |
| Current deferred revenue | 28.50M | 25.49M | 22.70M | 12.99M | 7.08M |
| Net debt | -57.82900M | -81.70000M | -134.45600M | -278.50700M | -364.61800M |
| Short term debt | 11.67M | 8.41M | 5.57M | 3.51M | 15.25M |
| Short long term debt | 6.30M | 4.66M | 0.56M | 0.58M | - |
| Short long term debt total | 33.02M | 17.02M | 33.17M | 18.09M | - |
| Other stockholder equity | 441.11M | 430.79M | 423.39M | -76.58900M | -39.68000M |
| Property plant equipment | - | - | - | 13.68M | 5.85M |
| Total current assets | 392.00M | 396.45M | 392.06M | 454.02M | 432.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 411.07M | 391.57M |
| Short term investments | 170.68M | 179.15M | 95.11M | 44.55M | - |
| Net receivables | 72.13M | 60.59M | 56.12M | 48.86M | 29.76M |
| Long term debt | 0.53M | 1.05M | 1.65M | 2.27M | - |
| Inventory | 48.43M | 43.89M | 60.88M | 48.15M | 32.17M |
| Accounts payable | 6.41M | 5.53M | 3.03M | 4.80M | 3.03M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.24M | 0.02M | -1.27500M | -0.69700M | 0.90M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.14M | 0.13M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -17.03000M | -19.60600M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 6.70M | 4.76M | 1.78M | 2.96M | 1.67M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 69.55M | 103.05M | 105.61M | 65.46M | 31.65M |
| Capital lease obligations | 16.92M | 11.31M | 11.92M | 12.31M | - |
| Long term debt total | - | - | - | 2.27M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 14.06M | -82.97400M | -174.02400M | -1.58700M | -20.99300M |
| Change to liabilities | - | - | - | 18.74M | 20.73M |
| Total cashflows from investing activities | 10.12M | -82.97400M | -93.89400M | -55.90900M | -20.99300M |
| Net borrowings | 0.84M | 3.62M | -0.56500M | 2.93M | -2.77200M |
| Total cash from financing activities | -13.43200M | -15.82200M | -41.81200M | 5.51M | 213.56M |
| Change to operating activities | - | - | - | -13.80400M | 1.03M |
| Net income | -66.53900M | -6.02000M | -12.14800M | 2.48M | 3.03M |
| Change in cash | -7.89200M | -68.88500M | -131.87000M | -65.11800M | 198.50M |
| Begin period cash flow | 98.75M | 167.63M | 299.50M | 364.62M | 166.12M |
| End period cash flow | 90.85M | 98.75M | 167.63M | 299.50M | 364.62M |
| Total cash from operating activities | -4.68600M | 25.38M | 5.28M | -12.23100M | 4.63M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 215.69M |
| Depreciation | 11.97M | 10.49M | 9.23M | 5.66M | 1.24M |
| Other cashflows from investing activities | -0.10700M | 0.08M | -0.17900M | -44.57400M | -16.62900M |
| Dividends paid | - | - | 1.47M | - | - |
| Change to inventory | -5.24400M | 14.76M | 4.29M | -17.65300M | -7.06800M |
| Change to account receivables | 0.37M | -5.42800M | -7.33200M | -19.74400M | -12.36700M |
| Sale purchase of stock | -15.07400M | -21.61100M | -44.15100M | 1.20M | 216.33M |
| Other cashflows from financing activities | -0.66900M | 2.17M | 2.90M | 4.36M | 0.64M |
| Change to netincome | - | - | - | 17.35M | 7.07M |
| Capital expenditures | 4.08M | 3.52M | 4.83M | 9.87M | 4.36M |
| Change receivables | - | - | - | -19.74400M | -12.36700M |
| Cash flows other operating | - | - | - | -15.90400M | -8.57800M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -62.62700M | 197.20M |
| Change in working capital | -4.79400M | 7.71M | -10.50900M | -39.92800M | -8.64600M |
| Stock based compensation | 24.59M | 26.85M | 22.05M | 16.59M | 6.59M |
| Other non cash items | -3.47000M | -10.76600M | -3.34000M | 2.96M | 1.97M |
| Free cash flow | -8.77000M | 21.85M | 0.45M | -22.09900M | 0.27M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences Inc |
0.23 5.96% | 4.09 | - | 370.37 | 2.92 | 1.72 | 1.74 | 222.69 |
| ABT Abbott Laboratories |
2.70 3.07% | 90.53 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
5.31 1.74% | 310.00 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
1.36 1.72% | 80.63 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.27 2.86% | 45.60 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
47215 Lakeview Blvd, Fremont, CA, United States, 94538-6407
| Name | Title | Year Born |
|---|---|---|
| Dr. Wenbin Jiang Ph.D. | Pres, CEO & Chairman | 1964 |
| Mr. Patrik Sebastian Jeanmonod | Chief Financial Officer | 1966 |
| Dr. Ming Yan Ph.D. | CTO & Director | 1963 |
| Dr. Allen B. Poirson Ph.D. | Sr. VP of Bus. & Corp. Devel. | 1960 |
| Mr. Chris Williams | Chief Operating Officer | NA |
| Mr. Mark Edinger | VP of Scientific Affairs | NA |
| Mr. Paul D. Goodson | Head of Investor Relations | NA |
| Ms. Valerie T. Barnett J.D. | Gen. Counsel & Corp. Sec. | 1975 |
| Ms. Connie Wedel | Chief People Officer | NA |
| Mr. Todd Garland | Chief Commercial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...